Caverject, Alprostadil Wire
Comprehensive News Feed for Caverject, Alprostadil (generic).
Results 1 - 20 of 25 in Caverject, Alprostadil (generic)
-
Emerging Stock Report Initiates Independent Research Coverage on NexMed, Inc.
Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on NexMed, Inc. Comment?
-
NexMed, Inc. to Acquire Bio-Quant, Inc.
Nov 23, 2009 - NexMed, Inc. , a developer of products based on the NexACT technology, today announced that it has entered into a definitive agreement to acquire Bio-Quant, Inc., a revenue generating privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in ... Comment?
-
Erectile Dysfunction Treatment: Alternatives to Pills
w/Photo
From the NYTimes : 30 million men in U.S. experience erectile dysfunction , 30% of men in their 50s, more than 50% of those in their 60s. Comment?
-
NexMed to Acquire Bio-Quant, Inc.
NexMed, Inc. , a developer of products based on the NexACT technology, today announced that it has entered into a definitive agreement to acquire Bio-Quant, Inc., a revenue generating privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Comment?
-
NexMed Receives Cash Infusion of $750,000
NexMed, Inc. , a developer of innovative transdermal products based on the NexACT drug delivery technology, today announced that it raised $750,000 in gross proceeds from the issuance of new convertible notes due December 31, 2011 , which are secured by a mortgage on NexMed's facility in East Windsor, New Jersey. Comment?
-
Causes, Symptoms, Treatment, Diagnosis
In this factsheet: Diagnosing Erectile Difficulties To find out what's causing erection problems, a doctor will begin by asking about other medical conditions the man might have, what medicines he's taking, when his erection problems occur, and what form they take. Comment?
-
NexMed Announces Third Quarter 2009 Financial Results Conference Call
NexMed, Inc. , a developer of innovative topical products based on the NexACT technology, today announced that management will hold a conference call to discuss 2009 third quarter financial results and ongoing corporate activities, on Tuesday, November 10, 2009 at 10:00 a.m. EST. Comment?
-
NexMed Confirms Nasdaq Hearing Date
NexMed, Inc. , a developer of products based on the NexACT technology, today announced that it has heard back from the Nasdaq Listing Qualifications Department regarding its request for a hearing concerning its possible delisting from the Nasdaq Capital Market, and that a hearing has been scheduled for Thursday, November 12, 2009. Comment?
-
NexMed Provides Update on Anti-Fungal Product
NexMed, Inc. , a developer of products based on the NexACT technology, today announced that it has completed its post hoc analysis of NM100060, the Company's topically-applied treatment for onychomycosis, commonly known as nail fungus. Comment?
-
NexMed Provides Update on Anti-Fungal Product; Seeks Partner for Further Development
NexMed, Inc., a developer of products based on the NexACTA technology, today announced that it has completed its post hoc analysis of NM100060, the Companya s topically-applied treatment for onychomycosis, commonly known as nail fungus. Comment?
-
FOXSexpert: Overcoming ED - The Return t
It's estimated that more than 100 million men worldwide are affected by erectile dysfunction . Comment?
-
FOXSexpert: Overcoming ED - The Return t
It's estimated that more than 100 million men worldwide are affected by erectile dysfunction . Comment?
-
Restoring a Healthy Sex Life: Erectile Dysfunction Outlooks and Options
w/Photo
It is minimally invasive and effective in producing consistent erections. And, as a localized treatment, there is little concern about its effects on the rest of the body, no risk to other health conditions and a low likelihood of contraindication. Comment?
-
Solve Erection Problems with Good Quality Erection Oils
Erection problems are quite common among elderly men but can easily be treated. Learn about erection problems, its causes and available treatment options. Comment?
-
Prostate Cancer and Sexual Dysfunction
Besides the usual symptoms like urinary retention, increase in urinary frequency, or the noticeable decrease in size and force of urination, one of the initial symptoms that is commonly experienced by men with Prostate Cancer is Sexual Dysfunction. Comment?
-
VIVUS to Host Conference Call and Webcast Discussion of Qnexa Phase 3 Results
VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, plans to announce the results from the EQUIP and CONQUER Qnexa phase 3 obesity clinical trials on September 9th prior to market open. Comment?
-
VIVUS to Present at Four Upcoming Healthcare Conferences
VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, Chief Financial Officer, will present an overview of the company at four healthcare investment conferences during the month of September. Comment?
-
Erectile dysfunction following prostatectomy: prevention and treatment.
Even with significant advances in surgical technique and superb results for cancer control and preservation of urinary function, erectile dysfunction following RP is a common complication. Comment?
-
NexMed Submits Compliance Plan to Nasdaq
NexMed, Inc. , a developer of innovative topical products based on the NexACT technology, today announced that it has submitted to Nasdaq its plan to achieve and sustain compliance with Marketplace Rule 4310 . Comment?
-
NexMed Receives Nasdaq Delisting Warning Letter
Aug 14, 2009 - NexMed, Inc. , a developer of innovative topical products based on the NexACT technology, today announced that it has received a notice from Nasdaq indicating that it does not comply with the minimum $2.5 million in stockholders' equity requirement for continued listing on the Nasdaq Capital Market set forth in Marketplace Rule 4310 ... Comment?
Caverject, Alprostadil Forum
Most Popular
- CNN: Obama Approval Rating Drops To All Time Low - 423 comments
- Palin Left Hawaii Because Of Too Many Asians: Father - 191 comments
- Judge: Parents bigots for opposing immoral lessons - 243 comments
- Helping all will help black Americans, Obama says - 92 comments
- Michelle Obama Wore Clothes to Light the Christmas Tree - 79 comments
- Turkey Has Voiced Concerns Over The Minaret Ban In Switzerland - 141 comments
- Obama Says He Concentrating on Jobs - 52 comments
- Indonesia: Citarum sungai terkotor dunia - 44 comments
- Mayor resists time-clock system for his office - 48 comments
- Dale Earnhardt Jr. In a Different Light - 55 comments
|
Reach local customers. Engage a specific demographic. Maximize business-to-business opportunities. Topix can deliver your message.
|
Copyright ©2009 Topix LLC
